Is acupuncture effective for lurbinectedin induced nausea?

Does acupuncture relieve lurbinectedin-induced nausea?

Acupuncture has shown modest benefit in reducing chemotherapy-induced nausea in general cancer patients, but specific data on lurbinectedin are absent. A 2023 meta-analysis of 27 trials found a statistically significant reduction in acute and delayed nausea severity with acupuncture compared with usual care or sham controls, yet effect sizes were small and many studies scored medium risk of bias [1].

Does lurbinectedin cause nausea at all?

Lurbinectedin monotherapy produces nausea in 48–78 % of patients, depending on the study population and grade definition. Most cases are mild to moderate (Grade 1–2), but severe (Grade 3) nausea occurs in 4–7 % of patients and requires dose interruption or reduction [2].

How does lurbinectedin compare with other chemo agents?

Lurbinectedin is a marine-derived DNA minor-groove binder delivered intravenously every 21 days. Unlike cisplatin, which is classified as a high-emetogenic-risk agent, lurbinectedin falls into the moderate-emetogenic-risk category under ASCO guidelines. Its profile is closer to topotecan than to anthracyclines or platinum compounds [2].

When does nausea typically start after lurbinectedin?

Nausea begins within 24 hours of infusion and peaks on days 2–3. Delayed nausea persisting beyond day 5 is less common than with high-emetogenic agents, but still occurs in a subset of patients. The manufacturer recommends 5-HT3 antagonists plus dexamethasone as primary prophylaxis [2].

Can patients add acupuncture to standard antiemetics?

No randomized trial has examined combining acupuncture with 5-HT3 antagonists or NK1 antagonists for lurbinectedin. General chemo-nausea guidelines allow non-pharmacologic options such as acupuncture for patients whose nausea persists despite optimized drug regimens. NCCN supportive-care guidelines rate acupuncture as a Category 2B recommendation for refractory chemotherapy nausea [3].

Why are drug companies interested in non-drug approaches?

Companies developing new oncology agents sometimes commission studies on adjunctive therapies to improve tolerability and keep patients on therapy. Current lurbinectedin development programs are focused on combination regimens rather than nausea management [2].